Search Results for “ Pfizer” – Page 16 – media

Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 594
- May 10, 2017
cancer clinic Company Insight FDA gentic
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 581
- May 10, 2017
antibody Bavencio cancer New Approvals
Over 5.7 billion! China’s dual antibody ADC goes global+1

On November 18th, VelaVigo Cayman Limited announced a global strategic partnership agreement with Avenzo Therapeutics, Inc. (Avenzo). According to the agreement, Orange Sail Pharmaceuticals will grant Avenzo the development, production, and commercialization of Nectin4/TROP2 bispecific antibody conjugates worldwide (excluding Greater China), while retaining relevant rights in Greater China. Both parties will jointly promote the development and clinical application of the project on a global scale. The project plans to submit an IND to the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China by 2025. According to the terms of the agreement, Orange Sail Pharmaceuticals will receive a down payment of up to $50 million and recent milestone payments. After achieving key milestones in development, regulatory approval, and sales, the company is expected to receive up to $750 million in follow-up milestone payments and tiered royalty payments based on sales in the Avenzo region. ...
- Source: drugdu
- 40
- November 21, 2024
Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding?

Jingtai Technology, which has the halo of being the “first AI pharmaceutical stock” in China, has attracted considerable attention in the secondary market. In the past few months, it has always sparked discussions within the industry due to occasional breakthroughs. According to Wind, on November 19th, Jingtai Technology’s lowest intraday price was HKD 3.51 per share, hitting a new low since its listing. The closing price for the day was HKD 4.00 per share, a drop of 12.66%. Compared to its issue price of HKD 5.28 per share, it has dropped 24.24%. In fact, since September this year, the stock price of Jingtai Technology has shown an overall fluctuating downward trend. According to the official website of Jingtai Technology, it is an innovative research and development platform company driven by artificial intelligence (AI) and robots. Based on technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale ...
- Source: drugdu
- 34
- November 21, 2024
Uncovering the truth of AbbVie’s $8.7 billion lesson

M&A is a metaphysics, with heaven on one side and hell on the other, tempting prominent names to enter. The latest to enter “hell” is AbbVie. On November 11, AbbVie announced that emraclidine, the “ace project” acquired by acquiring Cerevel for $8.7 billion at the end of last year, failed to reach the expected endpoint in two Phase II studies for schizophrenia, which cast a shadow on its future. As soon as the news came out, AbbVie’s stock price plummeted 12.57%, and its market value evaporated by more than $40 billion overnight. Once, this merger and acquisition was a “model” in the industry. From the first acquisition invitation to the final acquisition of Cerevil, AbbVie took less than two months. Fast, accurate, and ruthless, it foreshadowed AbbVie’s determination to deal with the patent cliff. But now, everything is coming to nothing. This once again allows us to see the “variables” ...
- Source: drugdu
- 49
- November 15, 2024
Global New Drug Progress and New Sharing

Progress in drug research and development 1. Anjin C5aR antagonist “Avamipram” approved for market in China On November 5th, the official website of NMPA announced that the marketing application for avacopan capsules jointly developed by Anjin and CSL Vifor has been approved, presumably for the treatment of anti neutrophil cytoplasmic antibody (ANCA) – related vasculitis (AAV). Afakepan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the allergen C5a, blocking C5a mediated neutrophil activation and migration. The drug was approved by the US FDA in October 2021 for use in combination with standard treatment regimens including glucocorticoids to treat adult active severe ANCA associated vasculitis (MPA and GPA). In July 2024, Anjin reached an agreement with CSL Vifor to acquire commercial rights to Avamipram in Asia and Latin America, including the mainland Chinese market. 2. Pfizer PARP inhibitor “Terazopanib” approved in China On November 5th, ...
- Source: drugdu
- 70
- November 8, 2024
MNCs in China, looking for a new era of survival philosophy

Multinational pharmaceutical companies are under increasing pressure. Especially when the US market, the world’s largest pharmaceutical market, has undergone tremendous changes due to the Inflation Reduction Act, the importance of the Chinese market has once again been highlighted. However, all signs indicate that it is becoming increasingly difficult to get a bigger piece of the pie in the Chinese market. In recent years, the reform policies introduced by the state at the pharmaceutical level have exceeded the changes in the previous decades. The continued advancement of medical reform policies such as medical insurance negotiations and national centralized procurement, coupled with the epidemic, anti-corruption, capital winter, local generic drugs, and the rise of innovative forces, have intensified the challenges of the entire industry. Therefore, we see that the past two years have become a strategic turbulence period for MNCs in China. While tapping the potential of the domestic market, they are ...
- Source: drugdu
- 68
- November 7, 2024
COVID-19 drugs have become a “dark horse”

The success and failure of COVID-19 are the market’s summary of Pfizer in the past few years. In 2022, COVID-19 vaccines and COVID-19 oral drugs brought Pfizer up to $57 billion in revenue. Relying on the wealth brought by COVID-19 products, Pfizer’s revenue exceeded $100 billion this year, setting a new record for the highest revenue of major pharmaceutical companies. However, as the COVID-19 pandemic dissipated, the global market demand for COVID-19 products fell sharply, and Pfizer was the first to bear the brunt. Faced with the “COVID-19 cliff”, Pfizer had to continue to lower its revenue expectations, and the company’s stock price continued to fall. Last year, it fell by more than 40% throughout the year, and its market value evaporated by nearly $130 billion. In this year’s third quarter report, Pfizer handed in a report card that far exceeded market expectations. Revenue in the third quarter reached $17.7 ...
- Source: drugdu
- 47
- November 5, 2024
After the guidelines were adjusted, GlaxoSmithKline’s RSV vaccine sales plummeted by 74%

Star vaccine products suffered a Waterloo. Last year, the RSV vaccine was amazing; this year, it fell back quickly. Recently, GlaxoSmithKline released its financial report, and its RSV vaccine Arexvy’s sales in the third quarter fell 74% year-on-year, with sales of 188 million pounds, equivalent to 240 million US dollars. So, what caused the decline of Arexvy? According to GlaxoSmithKline, Arexvy suffered a triple blow. The core is that the US Centers for Disease Control and Prevention (CDC) has narrowed the scope of immunization recommendations. Previously, RSV vaccines were recommended for vaccination for people over 60 years old. In June of this year, the US CDC adjusted its recommendations for vaccination populations. After the adjustment, the scope was greatly narrowed, limited to: 1. Adults aged 75 and above. 2. High-risk groups aged 60-74. In addition, the US CDC recommends that it be used only as a single lifetime vaccination. In ...
- Source: drugdu
- 39
- November 5, 2024
Aimei Vaccine’s 13-Valent Conjugate Pneumococcal Vaccine Obtains Production License and Market Registration Submitted

On November 1, Aimei Vaccine announced that it has submitted a drug market registration application for its self-developed 13-valent conjugate pneumococcal vaccine to the National Medical Products Administration. The results from a completed Phase III clinical study show that Aimei’s 13-valent conjugate pneumococcal vaccine has demonstrated good immunogenicity and safety, meeting the clinical preset objectives. Aimei’s wholly-owned subsidiary, Aimei Biotechnology Co., Ltd., has obtained the corresponding drug production license for this product. The 13-valent conjugate pneumococcal vaccine has been referred to as the “king of global vaccines” and has been the world’s top-selling vaccine for ten consecutive years. Pfizer’s 13-valent conjugate pneumococcal vaccine (Prevnar 13®) is the best-selling vaccine globally and has frequently ranked among the top ten best-selling drugs worldwide. According to Pfizer’s 2023 annual report, global sales of Pfizer’s pneumococcal conjugate vaccine were approximately $6.44 billion in 2023. Over the years, the global sales of the 13-valent conjugate ...
- Source: drugdu
- 43
- November 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.